N-oxide derivative 14a represents a promising new antiplatelet and antithrombotic prototype for the prevention of atherothrombotic events.
Answers are grounded in this paper and cite their sources.
Supports preclinical antithrombotic development of benzofuroxan derivatives; hypothesis-generating for human translation.
Thrombosis is the main outcome of many cardiovascular diseases. Current treatments to prevent thrombotic events involve the long-term use of antiplatelet drugs. However, this therapy has several limitations, thereby justifying the development of new drugs. A series of N-oxide derivatives (furoxan and benzofuroxan) were synthesized and characterized as potential antiplatelet/antithrombotic compounds. All compounds (3a,b, 4a,b, 8a,b, 9a,b, 13a,b and 14a,b) inhibited platelet aggregation induced by adenosine-5-diphosphate, collagen, and arachidonic acid. All compounds protected mice from pulmonary thromboembolism induced by a mixture of collagen and epinephrine; however, benzofuroxan derivatives (13a,b and 14a,b) were the most active compounds, reducing thromboembolic events by up to 80%. N-oxide derivative 14a did not induce genotoxicity in vivo. In conclusion, 14a has emerged as a new antiplatelet/antithrombotic prototype useful for the prevention of atherothrombotic events.
No takes yet. Share an insight, caveat, or question.
Rosseto et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: